Parkinson's disease historical perspective: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Parkinson's disease}} | {{Parkinson's disease}} | ||
{{CMG}} | {{CMG}} {{AE}} {{Fs}} | ||
==Overview== | ==Overview== | ||
Revision as of 15:28, 21 December 2018
|
Parkinson's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parkinson's disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Parkinson's disease historical perspective |
|
Risk calculators and risk factors for Parkinson's disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
the first person who documented and recognized Parkinson’s disease was a British physician, James Parkinson in 1817 who named it paralysis agitans. The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients. in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.
Historical Perspective
Discovery
- Parkinson disease’s symptoms have been known for many years but the first person who documented and recognized Parkinson’s disease was a British physician, James Parkinson in 1817 who named it paralysis agitans.
- The current name of the disease (Parkinson disease) is from Jean-Martin Charcot.
- The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients.
- Later on in 1919 Tretiakoff showed that in this patients’ substantia nigra there are evidences of neuronal loss.
- Finally in the 1950s dopamine depletion was known to be the underlying cause of the disease.[1]
- Later, in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.[2][3][4]
Landmark Events in the Development of Treatment Strategies
Famous Cases
References
- ↑ Hornykiewicz O (2006). "The discovery of dopamine deficiency in the parkinsonian brain". J. Neural Transm. Suppl. (70): 9–15. PMID 17017502.
- ↑ Manyam BV, Sánchez-Ramos JR (1999). "Traditional and complementary therapies in Parkinson's disease". Adv Neurol. 80: 565–74. PMID 10410773.
- ↑ Parkinson J (2002). "An essay on the shaking palsy. 1817". J Neuropsychiatry Clin Neurosci. 14 (2): 223–36, discussion 222. doi:10.1176/jnp.14.2.223. PMID 11983801.
- ↑ Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520.<ref name="pmid5637779">Cotzias GC (March 1968). "L-Dopa for Parkinsonism". N. Engl. J. Med. 278 (11): 630. PMID 5637779.